Drug Database · Clinicians

Teneligliptin

Brands (8) Digliptin, Glipten, Glypsa 20…Show all

Antidiabetic agent (dipeptidyl peptidase 4 (DPP-4) inhibitors); Dipeptidyl peptidase 4 (DPP-4) inhibitor; and others PH FDA category

Rx · Prescription drug8 PH productsVAT-exempt (some products) Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Contraindications

  • Severe ketosis, diabetic coma or precoma, type 1 diabetes
  • Severe infection, around surgery, serious trauma
  • Hypersensitivity
renalcarematters.com, reviewed

Dosing: Adult

  • Type 2 diabetes: 20 mg once daily; may increase to 40 mg once daily with close monitoring if response is inadequate
renalcarematters.com, reviewed

Dosing: Altered kidney function

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor cleared by both liver (CYP3A4, flavin monooxygenases) and kidney (15% to 22% unchanged in urine). Kidney impairment raises exposure only modestly (at most about 1.7-fold), and the Thai label, based on the Japanese originator, sets no kidney dose adjustment; hemodialysis removes about 16% of a dose. It has no US FDA label.

Kidney function measure: The label reports kidney pharmacokinetics by severity without numeric thresholds or dose changes; bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Usual: 20 mg once daily; may increase to 40 mg once daily with close monitoring (Thai SmPC).
CrCl 30–59 mL/min
The label gives no kidney dose change; exposure (AUC) was about 1.25-, 1.68- and 1.49-fold higher in mild, moderate and severe impairment (Thai SmPC). A dedicated PK study found no need for adjustment through end-stage kidney disease (Halabi 2013). The 40 mg dose was not studied in kidney impairment; increase only with close monitoring.
CrCl 15–29 mL/min
The label gives no kidney dose change; exposure (AUC) was about 1.25-, 1.68- and 1.49-fold higher in mild, moderate and severe impairment (Thai SmPC). A dedicated PK study found no need for adjustment through end-stage kidney disease (Halabi 2013). The 40 mg dose was not studied in kidney impairment; increase only with close monitoring.
CrCl <15 mL/min (not on dialysis)
The label gives no kidney dose change; exposure (AUC) was about 1.25-, 1.68- and 1.49-fold higher in mild, moderate and severe impairment (Thai SmPC). A dedicated PK study found no need for adjustment through end-stage kidney disease (Halabi 2013). The 40 mg dose was not studied in kidney impairment; increase only with close monitoring.
Hemodialysis (intermittent)
No dose change in the label; end-stage kidney failure AUC about 1.16-fold; hemodialysis removed 15.6% of the dose (Thai SmPC). Dialysis timing not critical.
Peritoneal dialysis
No PD data; no change expected from end-stage kidney failure data (AUC about 1.16-fold).
CRRT
No data. Insulin is usual in critical illness.
  • Dialyzable? Partly: hemodialysis removed 15.6% of the dose (Thai SmPC).
  • Monitoring Hypoglycemia with a sulfonylurea or insulin (lower their dose). Avoid with QT prolongation or torsades history; caution with class IA or III antiarrhythmics. Persistent severe abdominal pain (pancreatitis), intestinal obstruction in those with prior abdominal surgery (Thai SmPC). Caution in severe hepatic impairment (no experience). In dialysis patients, check QTc and electrolytes when other QT risk factors are present.
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: Thai FDA product information (September 2021). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Not established in children.
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 20 mg, 20 mg/15 mg

Registered products in the Philippines

8 products registered with the Food and Drug Administration (FDA) Philippines list Teneligliptin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Teneligliptin (as Hemipentahydrobromide hydrate) Tenglyn (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products8
Philippine FDA-registered products for Teneligliptin
Package insert
DigliptinTeneligliptin (as hydrobromide hydrate)
20 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Amb Hk Enterprises Inc.
DRP-16680
Jun 5, 2030
GliptenTeneligliptin (as Hydrobromide Hydrate)
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY45743
Jan 12, 2027
Glypsa 20Teneligliptin (as hydrobromide hydrate)
20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Saifen Drugs Philippines Inc.
DRP-16035
Oct 18, 2029
TenelizoneTeneligliptin (as hydrobromide hydrate + Pioglitazone (Hydrochloride)
20mg/ 15mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY47500
Nov 19, 2026
TenemaxTeneligliptin (as hydrobromide hydrate)
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
The Cathay Yss Distributors Co., Inc.
DR-XY47994
May 2, 2027
TenemedTeneligliptin
20 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 15's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Medinova Pharmaceutical Inc.
DR-XY49536
Oct 7, 2030
Tenepride-20Teneligliptin (as hydrobromide hydrate)
20 mg Film Coated tabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Importer: Brown & Burk Phils., Inc.
DR-XY48005
May 6, 2027
TenglynTeneligliptin (as Hemipentahydrobromide hydrate) TenglynVariant spelling
20 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's)
Rx
Cadila Healthcare LimitedIndia
Zydus Healthcare Philippines, Inc.
DR-XY47979
Apr 28, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Class IA (quinidine, procainamide) and class III (amiodarone, sotalol) antiarrhythmicsAdjust or monitorAdditive QT prolongation.Use with caution; avoid in QT prolongation.
Sulfonylureas, insulinAdjust or monitorMore hypoglycemia.Consider lowering their dose.
Ketoconazole (strong CYP3A4 inhibitor)MinorTeneligliptin AUC up about 1.49-fold.Monitor.
Beta-blockers, salicylates, MAO inhibitors; corticosteroids, thyroid hormone, epinephrineMinorIncrease or reduce glucose lowering.Monitor glucose.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Hypoglycemia (2.6%)
  • Constipation (0.9%)

Serious

  • Hypoglycemia (with sulfonylurea or insulin)
  • Intestinal obstruction (0.1%)
  • Acute pancreatitis
  • Hepatic dysfunction
  • Interstitial pneumonia
  • Bullous pemphigoid
  • QT prolongation
renalcarematters.com, reviewed

Monitoring parameters

  • Hypoglycemia with a sulfonylurea or insulin (lower their dose). Avoid with QT prolongation or torsades history; caution with class IA or III antiarrhythmics. Persistent severe abdominal pain (pancreatitis), intestinal obstruction in those with prior abdominal surgery (Thai SmPC). Caution in severe hepatic impairment (no experience). In dialysis patients, check QTc and electrolytes when other QT risk factors are present. Kidney
  • Glucose and HbA1c
  • ECG in patients with QT risk
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Time to peakDelayed by food (AUC unchanged)
Half-lifeAbout 24 hours (single dose); about 30 hours after 7 days
Half-life in kidney failure (ESKD) kidneyAUC up to about 1.68-fold (moderate impairment); 1.16-fold in end-stage kidney failure
Protein bindingAbout 78% to 82%
Metabolism (CYP, transporters)CYP3A4 and flavin-containing monooxygenases (FMO1, FMO3)
Renal excretion kidney14.8% to 22.1% unchanged in urine
Dialyzability kidney15.6% removed by hemodialysis
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Thai Food and Drug Administration. Tenelia 20 mg tablets SmPC (1C 15074/63 (NC)) [Thai FDA product information, September 2021; no US FDA label]. https://ndi.fda.moph.go.th/uploads/drug_detail_corporation/doc/word/1163/3b192a1e00da902ea978f0b2304c6b9c-a1.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Mitsubishi Tanabe Pharma (Thailand). (2021). Tenelia 20 mg tablets (teneligliptin hydrobromide hydrate) [Summary of product characteristics, authorization 1C 15074/63 (NC); text revised September 2021]. Thai Food and Drug Administration. https://ndi.fda.moph.go.th/uploads/drug_detail_corporation/doc/word/1163/3b192a1e00da902ea978f0b2304c6b9c-a1.pdf
  4. Halabi, A., Maatouk, H., Siegler, K. E., Faisst, N., Lufft, V., & Klause, N. (2013). Pharmacokinetics of teneligliptin in subjects with renal impairment. Clinical Pharmacology in Drug Development, 2(3), 246–254. https://doi.org/10.1002/cpdd.29

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .